drugset / Trial / NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/2
Recruiting
63 enrolled
Adrienne G. Waks
Eli Lilly and Company · collabVerastem, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Timeline
- Start
- 2023-02-23
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Avutometinib | Small molecule | — | Oral |
| Subject | Fulvestrant | Small molecule | — | Intramuscular |